5-alpha reductase type 2 Inhibitors
1 drugsAbout 5-alpha reductase type 2
5-alpha reductase type 2 is an enzyme that converts testosterone to dihydrotestosterone (DHT), a more potent androgen, playing a crucial role in male reproductive tissue development and function. Specifically, it is highly expressed in the prostate gland where it regulates androgen-mediated growth.
While there is currently no genetic evidence directly linking variations in the 5-alpha reductase type 2 gene to specific diseases, its role in androgen metabolism makes it a relevant drug target. Modulation of this enzyme's activity can influence conditions where androgen signaling is a contributing factor.
5-alpha reductase type 2 is targeted by one FDA-approved drug, AVODART (dutasteride), a small molecule used in other therapeutic areas. WAYLIS THERAP is the sole company with an approved drug for this target.
Strategic Insights
ℹ️ How we calculate- White space opportunity in Bladder Cancer with only 1 trials.
Top 5-alpha reductase type 2 Drugs
WAYLIS THERAP is the only company with an approved drug targeting 5-alpha reductase type 2.
The lack of competition suggests either high barriers to entry or limited market potential.
5-alpha reductase type 2 Drug Modality Landscape
Modalities
Routes of Administration
Only one approved drug targets 5-alpha reductase type 2, using small molecule modality.
Exploring alternative modalities like antibodies or PROTACs could provide a competitive advantage.
5-alpha reductase type 2 Clinical Trials 52 trials
Completion by Phase
| Phase | Total | Completed | Failed | Active | Completion |
|---|---|---|---|---|---|
| Phase 1 | 19 | 16 | 2 | 1 | 89% |
| Phase 2 | 16 | 9 | 5 | 2 | 64% |
| Phase 3 | 8 | 6 | 0 | 2 | 100% |
| Phase 4 | 9 | 8 | 1 | 0 | 89% |
Top Sponsors
By Modality
Top Conditions
Top Drugs
5-alpha reductase type 2 Drug Approval Timeline (2001 - 2001)
The first and only drug, AVODART, was approved in 2001.
The absence of recent approvals indicates a potentially saturated market or challenges in developing new therapies.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 1 companies competing
- • Market share by company
Full Drug Portfolio
- • All 1 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 1-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Competition: High (15 sponsors)
- • White space: 10 underexplored indications
- • Success rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Calculate These Metrics
Target Attractiveness Score
A 0-100 score based on trial activity, sponsor diversity, and completion rates. Calculated from 34 clinical trials targeting 5-alpha reductase type 2.
Completion rate: Percentage of trials that reached their planned endpoint. Trials terminated early, withdrawn, or suspended are not counted—these often indicate safety issues, lack of efficacy, or strategic pivots.
- Highly Attractive (80+): High trial activity, many sponsors, strong completion rates
- Attractive (60-79): Good trial activity and validation
- Moderate (40-59): Moderate interest from sponsors
- Low (under 40): Limited trial activity or validation concerns
Strategic Insights
Auto-generated insights based on trial analytics including competition intensity, white space opportunities, modality shifts, and failure patterns. We analyze trial sponsors, phases, indications, and outcomes.
Risk Signals
- High Competition: Many sponsors competing for this target (may reduce market opportunity)
- High Failure Risk: Low trial completion rates suggest development challenges
- Low Validation: Limited trial activity or poor outcomes indicate uncertain viability
- White Space Available: Underexplored indications present opportunities